11月21日，普莱柯盘中下跌2.03%，截至10:21，报13.54元/股，成交2581.59万元，换手率0.54%，总市 值46.86亿元。 资金流向方面，主力资金净流出28.53万元，大单买入337.15万元，占比13.06%，卖出365.68万元，占比 14.16%。 普莱柯所属申万行业为：农林牧渔-动物保健Ⅱ-动物保健Ⅲ。所属概念板块包括：动物疫苗、宠物经 济、医药电商、禽流感药物、疫苗等。 截至9月30日，普莱柯股东户数1.67万，较上期减少7.26%；人均流通股20739股，较上期增加7.83%。 2025年1月-9月，普莱柯实现营业收入8.23亿元，同比增长8.04%；归母净利润1.57亿元，同比增长 47.86%。 分红方面，普莱柯A股上市后累计派现11.25亿元。近三年，累计派现5.68亿元。 机构持仓方面，截止2025年9月30日，普莱柯十大流通股东中，国泰中证畜牧养殖ETF（159865）位居 第六大流通股东，持股547.16万股，相比上期增加202.17万股。香港中央结算有限公司位居第八大流通 股东，持股383.20万股，为新进股东。 责任编辑：小浪快报 普莱柯今年以来股价涨11.28 ...

（文章来源：证券时报网） 资金流入比率方面，贤丰控股、罗牛山、亨通股份等流入比率居前，主力资金净流入率分别为 26.79%、13.84%、8.61%。（数据宝） 动物疫苗概念资金流入榜 | 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 000735 | 罗牛山 | 7.27 | 11.47 | 15688.56 | 13.84 | | 002141 | 贤丰控 | 10.00 | 11.16 | 12366.15 | 26.79 | | 600226 | 亨通股 | 3.99 | 3.26 | 3745.10 | 8.61 | | 600201 | 生物股 | 1.98 | 4.26 | 1521.20 | 2.61 | | 002688 | 金河生 | -0.65 | 1.21 | 173.05 | 3.10 | | 603718 | 海利生 | 0.00 | 0.78 | -95.73 | -2.77 | | 6880 ...

Core Insights - Hualan Vaccine's stock price decreased by 2.02% on November 20, trading at 22.34 CNY per share with a market capitalization of 13.43 billion CNY [1] - The company has seen a year-to-date stock price increase of 33.63%, but a recent decline of 5.62% over the past five trading days [1] Financial Performance - For the period from January to September 2025, Hualan Vaccine reported a revenue of 806 million CNY, a year-on-year decrease of 15.81%, and a net profit attributable to shareholders of 132 million CNY, down 50.51% year-on-year [2] - Cumulative cash dividends since the company's A-share listing amount to 1.037 billion CNY, with 957 million CNY distributed over the past three years [3] Shareholder Structure - As of October 20, 2025, the number of shareholders for Hualan Vaccine stands at 17,000, with an average of 35,332 circulating shares per person [2] - The top ten circulating shareholders include notable entities such as the China Southern Asset Management Co., which has reduced its holdings by 43,990 shares [3]

Core Viewpoint - The stock of Jinyu Biological Technology Co., Ltd. has shown significant growth this year, with an 81.11% increase in share price, indicating strong market performance and investor interest [1][2]. Company Overview - Jinyu Biological Technology Co., Ltd. is located in Hohhot, Inner Mongolia, and was established on March 13, 1993, with its stock listed on January 15, 1999. The company primarily engages in the research, production, and sales of veterinary biological products [1]. - The main revenue composition includes 94.42% from biopharmaceuticals, 3.18% from other income, and 2.40% from supplementary sources [1]. Financial Performance - For the period from January to September 2025, the company achieved an operating income of 1.042 billion yuan, representing a year-on-year growth of 7.38%. However, the net profit attributable to shareholders decreased by 4.85% to 161 million yuan [2]. - The company has distributed a total of 2.219 billion yuan in dividends since its A-share listing, with 189 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 10.70% to 49,000, while the average circulating shares per person increased by 11.12% to 22,673 shares [2]. - Notable institutional shareholders include Guotai Zhongxin Livestock Breeding ETF, which holds 25.0398 million shares, and Hong Kong Central Clearing Limited, holding 21.1968 million shares, both showing increases in their holdings [3].

11月17日，温氏股份盘中下跌2.05%，截至09:55，报17.69元/股，成交2.44亿元，换手率0.23%，总市值 1177.08亿元。 分红方面，温氏股份A股上市后累计派现301.10亿元。近三年，累计派现69.35亿元。 资金流向方面，主力资金净流出1149.53万元，特大单买入702.43万元，占比2.88%，卖出1445.23万元， 占比5.93%；大单买入4298.48万元，占比17.63%，卖出4705.21万元，占比19.30%。 机构持仓方面，截止2025年9月30日，温氏股份十大流通股东中，香港中央结算有限公司位居第五大流 通股东，持股1.44亿股，相比上期增加550.13万股。易方达创业板ETF（159915）位居第九大流通股 东，持股1.13亿股，相比上期减少1909.10万股。 温氏股份今年以来股价涨10.48%，近5个交易日跌3.33%，近20日跌2.27%，近60日涨3.39%。 责任编辑：小浪快报 资料显示，温氏食品集团股份有限公司位于广东省云浮市新兴县新城镇东堤北路9号，成立日期1993年7 月26日，上市日期2015年11月2日，公司主营业务涉及肉鸡和肉猪养殖及其产品销 ...

Company Overview - KQ Bio, established on January 11, 2001, and listed on September 22, 2020, is located in Wuhan, Hubei Province. The company specializes in the research, production, and sales of veterinary biological products and animal epidemic prevention technology services [1][2]. - The main business revenue composition includes 94.64% from veterinary biological products, 4.46% from other sources, and 0.90% from supplementary services [1]. Financial Performance - For the period from January to September 2025, KQ Bio achieved a revenue of 738 million yuan, representing a year-on-year growth of 10.87%. The net profit attributable to the parent company was 338 million yuan, showing a year-on-year increase of 29.62% [2]. - Cumulative cash dividends since the A-share listing amount to 711 million yuan, with 488 million yuan distributed over the past three years [3]. Stock Performance - As of November 17, KQ Bio's stock price was 16.24 yuan per share, with a market capitalization of 7.57 billion yuan. The stock has increased by 17.15% year-to-date but has seen a decline of 0.43% over the last five trading days, 6.13% over the last 20 days, and 5.80% over the last 60 days [1]. - The number of shareholders as of September 30 was 9,713, an increase of 2.41% from the previous period, while the average circulating shares per person decreased by 2.36% to 47,990 shares [2]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the ninth largest circulating shareholder, holding 5.5731 million shares, an increase of 3.2155 million shares from the previous period [3].

Core Viewpoint - The stock of Jinyu Biological Technology Co., Ltd. has shown significant price movements, with a year-to-date increase of 58.86% and a recent trading volume indicating active market participation [1][2]. Company Overview - Jinyu Biological Technology Co., Ltd. is located in Hohhot, Inner Mongolia, and was established on March 13, 1993, with its stock listed on January 15, 1999. The company primarily engages in the research, production, and sales of veterinary biological products [1]. - The main revenue composition includes 94.42% from biopharmaceuticals, 3.18% from other income, and 2.40% from supplementary sources [1]. Financial Performance - For the period from January to September 2025, the company achieved an operating income of 1.042 billion yuan, representing a year-on-year growth of 7.38%. However, the net profit attributable to shareholders decreased by 4.85% to 161 million yuan [2]. - Cumulatively, the company has distributed 2.219 billion yuan in dividends since its A-share listing, with 189 million yuan distributed over the past three years [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 10.70% to 49,000, while the average number of tradable shares per person increased by 11.12% to 22,673 shares [2]. - Notable institutional holdings include the Guotai Zhongzheng Livestock Breeding ETF, which is the fourth-largest shareholder with 25.0398 million shares, an increase of 9.0897 million shares from the previous period [3].

Core Viewpoint - The stock of Wens Foodstuff Group Co., Ltd. has shown a positive trend with a 14.23% increase year-to-date, despite a slight decline in recent trading days [1][2]. Financial Performance - For the period from January to September 2025, Wens achieved a revenue of 758.17 billion yuan, reflecting a year-on-year growth of 0.53%. However, the net profit attributable to shareholders decreased by 17.98% to 52.56 billion yuan [2]. - Cumulatively, the company has distributed 301.10 billion yuan in dividends since its A-share listing, with 69.35 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Wens was 81,100, a decrease of 10.94% from the previous period. The average number of tradable shares per shareholder increased by 12.11% to 73,543 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 144 million shares, an increase of 5.50 million shares compared to the previous period. Conversely, E Fund's ChiNext ETF reduced its holdings by 19.09 million shares to 113 million shares [3]. Stock Market Activity - On November 10, Wens' stock price rose by 2.01% to 18.29 yuan per share, with a trading volume of 724 million yuan and a turnover rate of 0.67%. The total market capitalization reached 121.7 billion yuan [1]. - The net inflow of main funds was 32.71 million yuan, with significant buying and selling activities recorded [1].

Core Viewpoint - Kanghua Biotech's stock has shown significant growth this year, with a 51.82% increase, despite a decline in revenue and net profit for the first nine months of 2025 [1][2]. Group 1: Stock Performance - On November 7, Kanghua Biotech's stock rose by 2.01%, reaching 81.29 CNY per share, with a trading volume of 2.09 billion CNY and a turnover rate of 2.21% [1]. - The company's market capitalization stands at 10.563 billion CNY [1]. - Year-to-date, the stock has increased by 51.82%, with a 5.24% rise over the last five trading days, 5.57% over the last 20 days, and 4.03% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Kanghua Biotech reported a revenue of 840 million CNY, a year-on-year decrease of 20.78%, and a net profit attributable to shareholders of 189 million CNY, down 53.41% year-on-year [2]. - The company has distributed a total of 686 million CNY in dividends since its A-share listing, with 462 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased to 18,300, a rise of 6.13%, while the average number of circulating shares per person decreased by 8.10% to 6,502 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fifth largest with 1.1826 million shares, marking its entry as a new shareholder [3]. - The Southern CSI 1000 ETF is the seventh largest shareholder with 850,600 shares, having decreased its holdings by 11,000 shares compared to the previous period [3].

Core Viewpoint - TianKang Biological has shown a mixed performance in stock price and financial results, with a notable increase in stock price year-to-date but a decline in net profit for the recent period [1][2]. Group 1: Stock Performance - On November 7, TianKang Biological's stock rose by 2.03%, reaching 7.53 CNY per share, with a trading volume of 80.02 million CNY and a turnover rate of 0.79% [1]. - The stock has increased by 18.96% year-to-date, with a 2.03% rise in the last five trading days, a 2.46% decline over the last 20 days, and a 16.74% increase over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, TianKang Biological reported a revenue of 13.61 billion CNY, representing a year-on-year growth of 4.00%, while the net profit attributable to shareholders decreased by 27.20% to 412 million CNY [2]. - The company has distributed a total of 1.89 billion CNY in dividends since its A-share listing, with 598 million CNY distributed in the last three years [3]. Group 3: Business Overview - TianKang Biological, established on December 28, 2000, and listed on December 26, 2006, is based in Urumqi, Xinjiang, and specializes in the production and sales of biological vaccines for livestock, feed, and plant protein [1]. - The revenue composition of the company includes 32.20% from the pig breeding industry chain, 27.51% from feed, 16.37% from protein and oil processing, 14.75% from corn, 5.44% from veterinary drugs, and 3.40% from other sources [1]. Group 4: Shareholder Information - As of October 31, the number of shareholders for TianKang Biological was 58,000, a decrease of 3.11% from the previous period, with an average of 23,548 circulating shares per shareholder, an increase of 3.21% [2]. - Notable institutional holdings include Guotai Zhongzheng Livestock Breeding ETF as the fifth-largest shareholder with 24.30 million shares, and Hong Kong Central Clearing Limited as the seventh-largest shareholder with 15.03 million shares, marking a new entry [3].